Relapse Rates and Symptom Management Among Patients Receiving Natalizumab and other Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis
Nov 1, 2016, 00:00 AM
10.1016/j.jval.2016.09.464
https://www.valueinhealthjournal.com/article/S1098-3015(16)31831-9/fulltext
Section Title :
Disease-Specific Studies
Section Order :
441
First Page :
A427
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)31831-9&doi=10.1016/j.jval.2016.09.464